Advertisement

The Latest

As minimally and noninvasive clinical options continue to rise, spinal specialists are seeking innovative procedural alternatives to improve patient experience and diagnostic accuracy.

In a recent press release, Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain.

Advertisement